Alexander A. Khalessi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander A. Khalessi has a total of 255 co-authors. Here are the top co-authors by number of shared publications:
- David Rafael Santiago-Dieppa
University of California, San Diego, United States
19 shared publications Robert C. Rennert
Department of Neurosurgery, University of California, San Diego, La Jolla, CA, USA
14 shared publicationsJ. Scott Pannell
Department of Neurological Surgery, University of California, San Diego, CA, USA
13 shared publications- Peter Kan
Neurosurgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA
13 shared publications Arvin R. Wali
Department of Neurological Surgery, University of California, San Diego, CA, USA
12 shared publicationsJeffrey A. Steinberg
Department of Neurological Surgery, University of California, San Diego, CA, USA
12 shared publications
Latest Publications
- 3 November 2026
- Published by Wolters Kluwer Health in Neurosurgery
Two Decades of Neurosurgical Device Innovation: A Comprehensive Analysis of FDA Authorization Trends From 7800 Approvals by Subspecialty, Regulatory Pathway, and Approval Time
BACKGROUND AND OBJECTIVES: Technological progress has accelerated neurosurgical care, yet a panoramic view of these innovations remains lacking. This study aims to analyze all US Food and Drug Administration (FDA) authorizations issued from 2000 to 2023 to map neurosurgical device output by subspecialty, compare regulatory pathways and approval times, and identify factors affecting market entry. METHODS: All devices cleared or approved by the FDA Neurology and Orthopedic Review Panels (January 2000-December 2023) were extracted from publicly available 510(k), De Novo, Humanitarian Device Exemption, and Premarket Approval databases. Devices were assigned to 1 of 9 neurosurgical subspecialties and stratified by regulatory pathway, device class, company maturity, and geographic origin. Descriptive statistics, analysis of variance, and Welch t -tests assessed temporal and categorical differences. RESULTS: Of 16 064 devices reviewed by the FDA Neurology and Orthopedic panels, 7873 (49.0%) were neurosurgical, rising 172.1% over the period. Spine and peripheral nerve (5227 devices) and stereotactic and functional (1378) dominated volume and number of new market entries, while cerebrospinal fluid disorders (n = 149) and cranial trauma (n = 111) had fewer approvals. Cerebrovascular and endovascular (95.5%) and cranial trauma (200.0%) showed the largest growth rates, while cerebrospinal fluid disorders (−54.2%) and general cranial surgery (−34.5%) declined over time. Mean approval time varied by subspecialty ( P < .001), the shortest for spine and peripheral nerve (119.0 ± 102.7 days) and the longest for stereotactic and functional (158.7 ± 121.5 days). Approval or clearance times were strongly influenced by regulatory pathway and device class (both P < .001), with Premarket Approval devices (584.8 ± 323.3 days) the longest. Mature companies achieved faster approvals compared with startups (114.9 ± 97.0 vs 174.5 ± 133.9 days, P < .001). CONCLUSION: Neurosurgical device output has more than doubled, but volume concentrates where predicates are rich and reimbursement established, not where clinical need or novelty is the greatest. Pathway architecture, device complexity, and sponsor experience influence approval efficiency more than novelty.
- 3 November 2026
- Published by Wolters Kluwer Health in Neurosurgery
Two Decades of Neurosurgical Device Innovation: A Comprehensive Analysis of FDA Authorization Trends From 7800 Approvals by Subspecialty, Regulatory Pathway, and Approval Time
BACKGROUND AND OBJECTIVES: Technological progress has accelerated neurosurgical care, yet a panoramic view of these innovations remains lacking. This study aims to analyze all US Food and Drug Administration (FDA) authorizations issued from 2000 to 2023 to map neurosurgical device output by subspecialty, compare regulatory pathways and approval times, and identify factors affecting market entry. METHODS: All devices cleared or approved by the FDA Neurology and Orthopedic Review Panels (January 2000-December 2023) were extracted from publicly available 510(k), De Novo, Humanitarian Device Exemption, and Premarket Approval databases. Devices were assigned to 1 of 9 neurosurgical subspecialties and stratified by regulatory pathway, device class, company maturity, and geographic origin. Descriptive statistics, analysis of variance, and Welch t -tests assessed temporal and categorical differences. RESULTS: Of 16 064 devices reviewed by the FDA Neurology and Orthopedic panels, 7873 (49.0%) were neurosurgical, rising 172.1% over the period. Spine and peripheral nerve (5227 devices) and stereotactic and functional (1378) dominated volume and number of new market entries, while cerebrospinal fluid disorders (n = 149) and cranial trauma (n = 111) had fewer approvals. Cerebrovascular and endovascular (95.5%) and cranial trauma (200.0%) showed the largest growth rates, while cerebrospinal fluid disorders (−54.2%) and general cranial surgery (−34.5%) declined over time. Mean approval time varied by subspecialty ( P < .001), the shortest for spine and peripheral nerve (119.0 ± 102.7 days) and the longest for stereotactic and functional (158.7 ± 121.5 days). Approval or clearance times were strongly influenced by regulatory pathway and device class (both P < .001), with Premarket Approval devices (584.8 ± 323.3 days) the longest. Mature companies achieved faster approvals compared with startups (114.9 ± 97.0 vs 174.5 ± 133.9 days, P < .001). CONCLUSION: Neurosurgical device output has more than doubled, but volume concentrates where predicates are rich and reimbursement established, not where clinical need or novelty is the greatest. Pathway architecture, device complexity, and sponsor experience influence approval efficiency more than novelty.
- 26 March 2026
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 3 (4)
Health Systems Govern Only the Tip of the AI Iceberg
- 26 March 2026
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 3 (4)
Health Systems Govern Only the Tip of the AI Iceberg
- Open Access
- 6 February 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (3) , 108581
VISIION-L: Viz.ai implementation of stroke augmented intelligence and communications platform to improve indicators and outcomes for a comprehensive stroke center and network – Life Flight. A pilot experience
- 6 February 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (3) , 108581
Open AccessVISIION-L: Viz.ai implementation of stroke augmented intelligence and communications platform to improve indicators and outcomes for a comprehensive stroke center and network – Life Flight. A pilot experience
- 1 April 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 71 (Supplement) , N2
Presidential Preface to Clinical Neurosurgery Volume 71, Proceedings of the Congress of Neurological Surgeons 2024 Annual Meeting
- 1 April 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 71 (Supplement) , N2
Presidential Preface to Clinical Neurosurgery Volume 71, Proceedings of the Congress of Neurological Surgeons 2024 Annual Meeting
- 14 March 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 71 (Supplement) , 1-5
Presidential Address to the 2024 Annual Meeting of the Congress of Neurological Surgeons
- 14 March 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 71 (Supplement) , 1-5
Presidential Address to the 2024 Annual Meeting of the Congress of Neurological Surgeons
- 18 June 2024
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 41 (11-12) , 1375-1383
The Influence of Coagulopathy on Radiographic and Clinical Outcomes in Patients Undergoing Middle Meningeal Artery Embolization as Standalone Treatment for Non-acute Subdural Hematomas
Middle meningeal artery embolization (MMAE) is emerging as a safe and effective standalone intervention for non-acute subdural hematomas (NASHs); however, the risk of hematoma recurrence after MMAE in coagulopathic patients is unclear. To characterize the impact of coagulopathy on treatment outcomes, we analyzed a multi-institutional database of patients who underwent standalone MMAE as treatment for NASH. We classified 537 patients who underwent MMAE as a standalone intervention between 2019 and 2023 by coagulopathy status. Coagulopathy was defined as use of anticoagulation/antiplatelet agents or pre-operative thrombocytopenia (platelets p < 0.05). On matched multivariable analysis, patients with coagulopathy had an increased odds ratio (OR) of requiring surgical rescue (OR 3.95; 95% confidence interval [CI] 1.68–9.30; p < 0.01). Antiplatelet agent use (ticagrelor, prasugrel, or clopidogrel) was also predictive of surgical rescue (OR 4.38; 95% CI 1.51–12.72; p = 0.01), and patients with thrombocytopenia had significantly increased odds of in-hospital mortality (OR 5.16; 95% CI 2.38–11.20; p < 0.01). There were no differences in follow-up radiographic and other clinical outcomes in patients with and those without coagulopathy. Patients with coagulopathy undergoing standalone MMAE for treatment of NASH may have greater risk of requiring surgical rescue (particularly in patients using antiplatelet agents), and in-hospital mortality (in thrombocytopenic patients).
- 18 June 2024
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 41 (11-12) , 1375-1383
The Influence of Coagulopathy on Radiographic and Clinical Outcomes in Patients Undergoing Middle Meningeal Artery Embolization as Standalone Treatment for Non-acute Subdural Hematomas
Middle meningeal artery embolization (MMAE) is emerging as a safe and effective standalone intervention for non-acute subdural hematomas (NASHs); however, the risk of hematoma recurrence after MMAE in coagulopathic patients is unclear. To characterize the impact of coagulopathy on treatment outcomes, we analyzed a multi-institutional database of patients who underwent standalone MMAE as treatment for NASH. We classified 537 patients who underwent MMAE as a standalone intervention between 2019 and 2023 by coagulopathy status. Coagulopathy was defined as use of anticoagulation/antiplatelet agents or pre-operative thrombocytopenia (platelets p < 0.05). On matched multivariable analysis, patients with coagulopathy had an increased odds ratio (OR) of requiring surgical rescue (OR 3.95; 95% confidence interval [CI] 1.68–9.30; p < 0.01). Antiplatelet agent use (ticagrelor, prasugrel, or clopidogrel) was also predictive of surgical rescue (OR 4.38; 95% CI 1.51–12.72; p = 0.01), and patients with thrombocytopenia had significantly increased odds of in-hospital mortality (OR 5.16; 95% CI 2.38–11.20; p < 0.01). There were no differences in follow-up radiographic and other clinical outcomes in patients with and those without coagulopathy. Patients with coagulopathy undergoing standalone MMAE for treatment of NASH may have greater risk of requiring surgical rescue (particularly in patients using antiplatelet agents), and in-hospital mortality (in thrombocytopenic patients).
- 10 August 2023
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 32 (10) , 107303
(VISIION-S): Viz.ai Implementation of Stroke augmented Intelligence and communications platform to improve Indicators and Outcomes for a comprehensive stroke center and Network – Sustainability
- 10 August 2023
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 32 (10) , 107303
(VISIION-S): Viz.ai Implementation of Stroke augmented Intelligence and communications platform to improve Indicators and Outcomes for a comprehensive stroke center and Network – Sustainability
- Top Cited Papers
- 1 May 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 307 (4) , 222045
Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Predictors of Clinical and Radiographic Failure from 636 Embolizations
Background Knowledge regarding predictors of clinical and radiographic failures of middle meningeal artery (MMA) embolization (MMAE) treatment for chronic subdural hematoma (CSDH) is limited. Purpose To identify predictors of MMAE treatment failure for CSDH. Materials and Methods In this retrospective study, consecutive patients who underwent MMAE for CSDH from February 2018 to April 2022 at 13 U.S. centers were included. Clinical failure was defined as hematoma reaccumulation and/or neurologic deterioration requiring rescue surgery. Radiographic failure was defined as a maximal hematoma thickness reduction less than 50% at last imaging (minimum 2 weeks of head CT follow-up). Multivariable logistic regression models were constructed to identify independent failure predictors, controlling for age, sex, concurrent surgical evacuation, midline shift, hematoma thickness, and pretreatment baseline antiplatelet and anticoagulation therapy. Results Overall, 530 patients (mean age, 71.9 years ± 12.8 [SD]; 386 men; 106 with bilateral lesions) underwent 636 MMAE procedures. At presentation, the median CSDH thickness was 15 mm and 31.3% (166 of 530) and 21.7% (115 of 530) of patients were receiving antiplatelet and anticoagulation medications, respectively. Clinical failure occurred in 36 of 530 patients (6.8%, over a median follow-up of 4.1 months) and radiographic failure occurred in 26.3% (137 of 522) of procedures. At multivariable analysis, independent predictors of clinical failure were pretreatment anticoagulation therapy (odds ratio [OR], 3.23; P = .007) and an MMA diameter less than 1.5 mm (OR, 2.52; P = .027), while liquid embolic agents were associated with nonfailure (OR, 0.32; P = .011). For radiographic failure, female sex (OR, 0.36; P = .001), concurrent surgical evacuation (OR, 0.43; P = .009), and a longer imaging follow-up time were associated with nonfailure. Conversely, MMA diameter less than 1.5 mm (OR, 1.7; P = .044), midline shift (OR, 1.1; P = .02), and superselective MMA catheterization (without targeting the main MMA trunk) (OR, 2; P = .029) were associated with radiographic failure. Sensitivity analyses retained these associations. Conclusion Multiple independent predictors of failure of MMAE treatment for chronic subdural hematomas were identified, with small diameter (Supplemental material is available for this article. See also the editorial by Chaudhary and Gemmete in this issue.
- 1 May 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 307 (4) , 222045
Top Cited PapersMiddle Meningeal Artery Embolization for Chronic Subdural Hematoma: Predictors of Clinical and Radiographic Failure from 636 Embolizations
Background Knowledge regarding predictors of clinical and radiographic failures of middle meningeal artery (MMA) embolization (MMAE) treatment for chronic subdural hematoma (CSDH) is limited. Purpose To identify predictors of MMAE treatment failure for CSDH. Materials and Methods In this retrospective study, consecutive patients who underwent MMAE for CSDH from February 2018 to April 2022 at 13 U.S. centers were included. Clinical failure was defined as hematoma reaccumulation and/or neurologic deterioration requiring rescue surgery. Radiographic failure was defined as a maximal hematoma thickness reduction less than 50% at last imaging (minimum 2 weeks of head CT follow-up). Multivariable logistic regression models were constructed to identify independent failure predictors, controlling for age, sex, concurrent surgical evacuation, midline shift, hematoma thickness, and pretreatment baseline antiplatelet and anticoagulation therapy. Results Overall, 530 patients (mean age, 71.9 years ± 12.8 [SD]; 386 men; 106 with bilateral lesions) underwent 636 MMAE procedures. At presentation, the median CSDH thickness was 15 mm and 31.3% (166 of 530) and 21.7% (115 of 530) of patients were receiving antiplatelet and anticoagulation medications, respectively. Clinical failure occurred in 36 of 530 patients (6.8%, over a median follow-up of 4.1 months) and radiographic failure occurred in 26.3% (137 of 522) of procedures. At multivariable analysis, independent predictors of clinical failure were pretreatment anticoagulation therapy (odds ratio [OR], 3.23; P = .007) and an MMA diameter less than 1.5 mm (OR, 2.52; P = .027), while liquid embolic agents were associated with nonfailure (OR, 0.32; P = .011). For radiographic failure, female sex (OR, 0.36; P = .001), concurrent surgical evacuation (OR, 0.43; P = .009), and a longer imaging follow-up time were associated with nonfailure. Conversely, MMA diameter less than 1.5 mm (OR, 1.7; P = .044), midline shift (OR, 1.1; P = .02), and superselective MMA catheterization (without targeting the main MMA trunk) (OR, 2; P = .029) were associated with radiographic failure. Sensitivity analyses retained these associations. Conclusion Multiple independent predictors of failure of MMAE treatment for chronic subdural hematomas were identified, with small diameter (Supplemental material is available for this article. See also the editorial by Chaudhary and Gemmete in this issue.
- 1 November 2022
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 24 (1) , 80-87
Physiological Responses and Training Satisfaction During National Rollout of a Neurosurgical Intraoperative Catastrophe Simulator for Resident Training
BACKGROUND: Systematic use of neurosurgical training simulators across institutions is significantly hindered by logistical and financial constraints. OBJECTIVE: To evaluate feasibility of large-scale implementation of an intraoperative catastrophe simulation, we introduced a highly portable and low-cost immersive neurosurgical simulator into a nationwide curriculum for neurosurgery residents, during years 2016 to 2019. METHODS: The simulator was deployed at 9 Society of Neurological Surgeons junior resident courses and a Congress of Neurological Surgeons education course for a cohort of 526 residents. Heart rate was tracked to monitor physiological responses to simulated stress. Experiential survey data were collected to evaluate simulator fidelity and resident attitudes toward simulation. RESULTS: Residents rated the simulator positively with a statistically significant increase in satisfaction over time accompanying refinements in the simulator model and clinical scenario. The simulated complications induced stress-related tachycardia in most participants (n = 249); however, a cohort of participants was identified that experienced significant bradycardia (n = 24) in response to simulated stress. CONCLUSION: Incorporation of immersive neurosurgical simulation into the US national curriculum is logistically feasible and cost-effective for neurosurgical learners. Participant surveys and physiological data suggest that the simulation model recreates the situational physiological stress experienced during practice in the live clinical environment. Simulation may provide an opportunity to identify trainees with maladaptive responses to operative stress who could benefit from additional simulated exposure to mitigate stress impacts on performance.
- 1 November 2022
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 24 (1) , 80-87
Physiological Responses and Training Satisfaction During National Rollout of a Neurosurgical Intraoperative Catastrophe Simulator for Resident Training
BACKGROUND: Systematic use of neurosurgical training simulators across institutions is significantly hindered by logistical and financial constraints. OBJECTIVE: To evaluate feasibility of large-scale implementation of an intraoperative catastrophe simulation, we introduced a highly portable and low-cost immersive neurosurgical simulator into a nationwide curriculum for neurosurgery residents, during years 2016 to 2019. METHODS: The simulator was deployed at 9 Society of Neurological Surgeons junior resident courses and a Congress of Neurological Surgeons education course for a cohort of 526 residents. Heart rate was tracked to monitor physiological responses to simulated stress. Experiential survey data were collected to evaluate simulator fidelity and resident attitudes toward simulation. RESULTS: Residents rated the simulator positively with a statistically significant increase in satisfaction over time accompanying refinements in the simulator model and clinical scenario. The simulated complications induced stress-related tachycardia in most participants (n = 249); however, a cohort of participants was identified that experienced significant bradycardia (n = 24) in response to simulated stress. CONCLUSION: Incorporation of immersive neurosurgical simulation into the US national curriculum is logistically feasible and cost-effective for neurosurgical learners. Participant surveys and physiological data suggest that the simulation model recreates the situational physiological stress experienced during practice in the live clinical environment. Simulation may provide an opportunity to identify trainees with maladaptive responses to operative stress who could benefit from additional simulated exposure to mitigate stress impacts on performance.
- Open Access
- 30 March 2022
- Published by Springer Nature in Cureus
- Vol. 14 (3) , e23662
Robotics and Artificial Intelligence in Endovascular Neurosurgery
The use of artificial intelligence (AI) and robotics in endovascular neurosurgery promises to transform neurovascular care. We present a review of the recently published neurosurgical literature on artificial intelligence and robotics in endovascular neurosurgery to provide insights into the current advances and applications of this technology. The PubMed database was searched for "neurosurgery" OR "endovascular" OR "interventional" AND "robotics" OR "artificial intelligence" between January 2016 and August 2021. A total of 1296 articles were identified, and after applying the inclusion and exclusion criteria, 38 manuscripts were selected for review and analysis. These manuscripts were divided into four categories: 1) robotics and AI for the diagnosis of cerebrovascular pathology, 2) robotics and AI for the treatment of cerebrovascular pathology, 3) robotics and AI for training in neuroendovascular procedures, and 4) robotics and AI for clinical outcome optimization. The 38 articles presented include 23 articles on AI-based diagnosis of cerebrovascular disease, 10 articles on AI-based treatment of cerebrovascular disease, two articles on AI-based training techniques for neuroendovascular procedures, and three articles reporting AI prediction models of clinical outcomes in vascular disorders of the brain. Innovation with robotics and AI focus on diagnostic efficiency, optimizing treatment and interventional procedures, improving physician procedural performance, and predicting clinical outcomes with the use of artificial intelligence and robotics. Experimental studies with robotic systems have demonstrated safety and efficacy in treating cerebrovascular disorders, and novel microcatheterization techniques may permit access to deeper brain regions. Other studies show that pre-procedural simulations increase overall physician performance. Artificial intelligence also shows superiority over existing statistical tools in predicting clinical outcomes. The recent advances and current usage of robotics and AI in the endovascular neurosurgery field suggest that the collaboration between physicians and machines has a bright future for the improvement of patient care. The aim of this work is to equip the medical readership, in particular the neurosurgical specialty, with tools to better understand and apply findings from research on artificial intelligence and robotics in endovascular neurosurgery.
- 30 March 2022
- Published by Springer Nature in Cureus
- Vol. 14 (3) , e23662
Open AccessRobotics and Artificial Intelligence in Endovascular Neurosurgery
The use of artificial intelligence (AI) and robotics in endovascular neurosurgery promises to transform neurovascular care. We present a review of the recently published neurosurgical literature on artificial intelligence and robotics in endovascular neurosurgery to provide insights into the current advances and applications of this technology. The PubMed database was searched for "neurosurgery" OR "endovascular" OR "interventional" AND "robotics" OR "artificial intelligence" between January 2016 and August 2021. A total of 1296 articles were identified, and after applying the inclusion and exclusion criteria, 38 manuscripts were selected for review and analysis. These manuscripts were divided into four categories: 1) robotics and AI for the diagnosis of cerebrovascular pathology, 2) robotics and AI for the treatment of cerebrovascular pathology, 3) robotics and AI for training in neuroendovascular procedures, and 4) robotics and AI for clinical outcome optimization. The 38 articles presented include 23 articles on AI-based diagnosis of cerebrovascular disease, 10 articles on AI-based treatment of cerebrovascular disease, two articles on AI-based training techniques for neuroendovascular procedures, and three articles reporting AI prediction models of clinical outcomes in vascular disorders of the brain. Innovation with robotics and AI focus on diagnostic efficiency, optimizing treatment and interventional procedures, improving physician procedural performance, and predicting clinical outcomes with the use of artificial intelligence and robotics. Experimental studies with robotic systems have demonstrated safety and efficacy in treating cerebrovascular disorders, and novel microcatheterization techniques may permit access to deeper brain regions. Other studies show that pre-procedural simulations increase overall physician performance. Artificial intelligence also shows superiority over existing statistical tools in predicting clinical outcomes. The recent advances and current usage of robotics and AI in the endovascular neurosurgery field suggest that the collaboration between physicians and machines has a bright future for the improvement of patient care. The aim of this work is to equip the medical readership, in particular the neurosurgical specialty, with tools to better understand and apply findings from research on artificial intelligence and robotics in endovascular neurosurgery.